{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Covid+19&page=9",
    "query": {
      "condition": "Covid 19",
      "page": 9
    },
    "page_size": 10
  },
  "pagination": {
    "page": 9,
    "page_size": 10,
    "total_count": 2350,
    "total_pages": 235,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Covid+19&page=10&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Covid+19&page=8&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-04T12:52:22.015Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04443803",
      "title": "Characterizing the Perioperative Epidemiology of SARS-CoV-2 (COVID-19) Spread for Quality Improvement of Perioperative Infection Control Program",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Randy Loftus",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 11,
      "start_date": "2020-07-01",
      "completion_date": "2020-12-31",
      "has_results": false,
      "last_update_posted_date": "2021-07-12",
      "last_synced_at": "2026-11-04T12:52:22.015Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04443803"
    },
    {
      "nct_id": "NCT04924660",
      "title": "Novel Experimental COVID-19 Therapies Affecting Host Response",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "COVID-19",
        "SARS-CoV-2 Infection",
        "Coronavirus Infection"
      ],
      "interventions": [
        {
          "name": "TXA127",
          "type": "DRUG"
        },
        {
          "name": "TRV027",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Fostamatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sean Collins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1060,
      "start_date": "2021-07-15",
      "completion_date": "2023-12-31",
      "has_results": true,
      "last_update_posted_date": "2025-01-22",
      "last_synced_at": "2026-11-04T12:52:22.015Z",
      "location_count": 51,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Los Angeles, California + 40 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04924660"
    },
    {
      "nct_id": "NCT04562246",
      "title": "SARS-CoV-2 IgG and IgM Serologic Assays",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "Serologic assays for antibodies to SARS-CoV-2",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Henry Ford Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 214,
      "start_date": "2020-08-14",
      "completion_date": "2024-02-26",
      "has_results": false,
      "last_update_posted_date": "2024-02-28",
      "last_synced_at": "2026-11-04T12:52:22.015Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04562246"
    },
    {
      "nct_id": "NCT04762680",
      "title": "Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3159,
      "start_date": "2021-02-24",
      "completion_date": "2023-06-29",
      "has_results": true,
      "last_update_posted_date": "2025-09-18",
      "last_synced_at": "2026-11-04T12:52:22.015Z",
      "location_count": 30,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 26 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04762680"
    },
    {
      "nct_id": "NCT06603090",
      "title": "Text4Vax: Text Message Reminders for Pediatric COVID-19 and Influenza Vaccines 2024-25 Season",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Influenza",
        "COVID-19",
        "Vaccination Hesitancy"
      ],
      "interventions": [
        {
          "name": "Text message influenza vaccine reminders",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Text message COVID-19 vaccine reminders",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Text message influenza and COVID-19 vaccine reminders",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Months to 17 Years"
      },
      "enrollment_count": 66147,
      "start_date": "2024-10-02",
      "completion_date": "2025-04-30",
      "has_results": false,
      "last_update_posted_date": "2025-07-11",
      "last_synced_at": "2026-11-04T12:52:22.015Z",
      "location_count": 4,
      "location_summary": "Itasca, Illinois • New York, New York • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Itasca",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06603090"
    },
    {
      "nct_id": "NCT04876417",
      "title": "Transcranial Direct Current Stimulation (tDCS) for Post COVID-19 Fatigue",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Post Covid-19 Patients"
      ],
      "interventions": [
        {
          "name": "Transcranial Direct Current Stimulation",
          "type": "DEVICE"
        },
        {
          "name": "Sham Transcranial Direct Current Stimulation",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of Iowa",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 74,
      "start_date": "2022-06-15",
      "completion_date": "2023-04-30",
      "has_results": true,
      "last_update_posted_date": "2024-05-01",
      "last_synced_at": "2026-11-04T12:52:22.015Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04876417"
    },
    {
      "nct_id": "NCT04358068",
      "title": "Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19",
        "SARS-CoV 2"
      ],
      "interventions": [
        {
          "name": "Hydroxychloroquine (HCQ)",
          "type": "DRUG"
        },
        {
          "name": "Azithromycin (Azithro)",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Azithromycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2020-05-13",
      "completion_date": "2020-07-08",
      "has_results": true,
      "last_update_posted_date": "2021-11-16",
      "last_synced_at": "2026-11-04T12:52:22.015Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • San Diego, California • Torrance, California + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04358068"
    },
    {
      "nct_id": "NCT04977050",
      "title": "The Role of Frequent Point-of-care Molecular Workplace Surveillance for Miners",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "Quidel quickvue antigen test for COVID-19",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "University of New Mexico",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 230,
      "start_date": "2021-02-22",
      "completion_date": "2022-10-31",
      "has_results": true,
      "last_update_posted_date": "2024-04-03",
      "last_synced_at": "2026-11-04T12:52:22.015Z",
      "location_count": 1,
      "location_summary": "Albuquerque, New Mexico",
      "locations": [
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04977050"
    },
    {
      "nct_id": "NCT06402318",
      "title": "Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "COVID-19",
        "SARS CoV 2 Virus",
        "COVID-19 Pneumonia",
        "COVID-19 Respiratory Infection",
        "COVID-19 Acute Respiratory Distress Syndrome"
      ],
      "interventions": [
        {
          "name": "A&M Breathalyzer PROTECT Kiosk",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "The Geneva Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 100,
      "start_date": "2023-12-27",
      "completion_date": "2026-03-30",
      "has_results": false,
      "last_update_posted_date": "2025-12-10",
      "last_synced_at": "2026-11-04T12:52:22.015Z",
      "location_count": 1,
      "location_summary": "Fort Sam Houston, Texas",
      "locations": [
        {
          "city": "Fort Sam Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06402318"
    },
    {
      "nct_id": "NCT04988152",
      "title": "A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "sotrovimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo to Biologic",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Vir Biotechnology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 48,
      "start_date": "2021-07-06",
      "completion_date": "2021-12-07",
      "has_results": true,
      "last_update_posted_date": "2024-06-07",
      "last_synced_at": "2026-11-04T12:52:22.015Z",
      "location_count": 2,
      "location_summary": "Anaheim, California • Glendale, California",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04988152"
    }
  ]
}